Radius Health, Inc.
If you purchased Radius Health, Inc. securities and would like to join the action, please click "Join This Action" below.
RDUS STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF RADIUS HEALTH, INC. IS FAIR TO SHAREHOLDERS
June 23, 2022.
New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Radius Health, Inc. (NASDAQ: RDUS) to Gurnet Point Capital and Patient Square Capital is fair to Radius Health shareholders. Under the terms of the merger agreement, Gurnet Point and Patient Square will acquire all of the outstanding shares of Radius for $10.00 per share in cash plus a Contingent Value Right of $1.00 per share payable upon TYMLOS® (abaloparatide) net sales reaching $300 million (inclusive of U.S. sales and Japan royalties or supply payments based on supply of TYMLOS for sale in Japan) during any consecutive 12-month period prior to December 31, 2025.
The investigation concerns whether Radius and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Radius shareholders; (2) determine whether Gurnet Point and Patient Square are underpaying for Radius; and (3) disclose all material information necessary for Radius shareholders to adequately assess and value the merger consideration. On behalf of Radius shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.